


EXPRESS MAIL CERTIFICATE

Date 9/19/03 Docket No. 4306628295-US  
hereby certify that, on the date indicated above, this paper or fee was  
deposited with the U.S. Postal Service & that it was addressed for  
delivery to the Commissioner for Patents, PO Box 1450, Alexandria, VA  
22313-1450 by "Express Mail Post Office to Addressee" service.

 Name (Print)

 Signature

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00  
OR CREDIT ANY EXCESS IN THE FEES DUE WITH  
THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO.  
04-0100

Customer No.: 07278 Docket No.: 05986/100K433-US2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Bias FRANGIONE; et al.

Serial No.: NOT YET ASSIGNED

Confirmation No.:

Filed: CONCURRENTLY HEREWITH

For: SYNTHETIC IMMUNOGENIC BUT NON-AMYLOIDOGENIC PEPTIDES  
HOMOLOGOUS TO AMYLOID  $\beta$  FOR INDUCTION OF AN IMMUNE  
RESPONSE TO AMYLOID  $\beta$  AND AMYLOID DEPOSITS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

In order to comply with 37 CFR 1.97 and 1.98, attached hereto is a copy of  
Form PTO/SB/08A. Copies of the documents listed thereon were filed in the related  
application Serial No. 09/861,847, filed May 22, 2001.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing Form PTO-1449 next to the document. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

This submission is filed before a first action on the merits has been mailed.

The present Information Disclosure Statement is being submitted in compliance with 37 CFR 1.56, but the citation of such document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

It is believed that no fee is due. However, if the Commissioner determines that a fee is due, the Commissioner is hereby authorized to charge Deposit Account No. 04-0100 for any deficiency.

Early and favorable consideration is earnestly solicited.

Dated: September 19, 2003

Respectfully submitted,

  
\_\_\_\_\_  
Paul F. Fehlner, Ph.D.  
Registration No. 35,135  
Attorney for Applicant(s)

DARBY & DARBY  
Post Office Box 5257  
New York, NY 10150-5257  
(212) 527-7700

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid CMB control number.

Substitute for form 1449A/B/PTO				<i>Complete if Known</i>	
				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Bias Frangione
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	05986/100K433-US2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
					T <sup>4</sup>

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>1</sup> -Number <sup>1</sup> -Kind Code <sup>2</sup> (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	BA	WO 99/27944	6/10/1999	PCT A61K 38/00	
	BB	WO 95/31996	11/30/1995	PCT A61K 38/17	
	BC	WO 96/39834	12/19/1996	[PCT] A01N 43/40	
	BD	WO 99/279949	6/10/2000	[PCT] A61K 38/17	
	BE	WO 00/72880	12/07/2000	[PCT] A61K 39/395	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	CA	Frenkel, D. et al.: "Modulation of Alzheimer's beta-amyloid neurotoxicity by site-directed single-chain antibody." NEUROIMMUNOMODULATION, vol. 6, no. 6, November 1999 (1999-11),page 444 XP008000881, 4 <sup>th</sup> International Congress of the International Society for Neuroimmunomodulation; Lugano, Switzerland; September 29-October 2, 1999; ISSN: 1021-7401, abstract.			
	CB	Solomon, B. et al.: "Disaggregation of Alzheimer Beta-Amyloid by Site-Directed Mab" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, Washington, US, vol. 94, April 1997 (1997-04), pages 4109-4112, XP002911322, ISSN: 0027-8424, the whole document.			
	CC	Sigurdsson, Einar M. et al.: "Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice." AMERICAN JOURNAL OF PATHOLOGY, vol. 159, no. 2, August 2001 (2001-08), pages 439-447, XP008000840, ISSN: 0002-9440, the whole document.			
	CD	Schenk, Dale et al.: "Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse." NATURE, 1999,400, pages 173-177.			
	CE	Aguado, T. et al.: "Meeting Report - Novel adjuvants currently in clinical testing November 2-4, 1998, Foundation Mérieux, Annecy, France: A meeting sponsored by the World Health Organization." VACCINE 17 (1999); pages 2321-2328.			
	CF	Palmito, Monica M. et al.: "Recognition Sequence Design for Peptidyl Modulators of beta-Amyloid Aggregation and Toxicity." BIOCHEMISTRY 1999, 38, pages 3570-3578.			
	CG	Futaki, S. et al.: "Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery." J Biol. Chem. 2001, Feb. 23, 276 (8): 5835-40, abstract.			

Examiner Signature	Date Considered

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<i>Complete if Known</i>	
				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Blas Frangione
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	05986/100K433-US2

CH	Martinez-Fong, D. et al.: "Nonenzymatic glycosylation of poly-L-lysine: a new tool for targeted gene delivery." <i>Hepatology</i> 1994 Dec; 20(6): 1602-8.	
CI	Schwarzenberger, P. et al.: "Poly-L-lysine-based molecular conjugate vectors: a high efficiency gene transfer system for human progenitor and leukemia cells." <i>Am J Med Sci</i> 2001 Feb; 321 (2): 129-36.	
CJ	Wang, Y. et al.: "Endocytosis of horseradish peroxidase-poly-lysine conjugate by glomerular epithelial cells: an in vivo study." <i>J Pathol</i> 1989 Oct; 159(2): 159-67.	
CK	Shen, W.C. et al.: "Disulfide spacer between methotrexate and poly(D-lysine). A probe for exploring the reductive process in endocytosis." <i>J Biol Chem</i> 1985 Sep 15; 260(20): 10905-8.	
CL	Peterson, P.K. et al.: "Polyamino acid enhancement of bacterial phagocytosis by human polymorphonuclear leukocytes and peritoneal macrophages." <i>Infect Immun</i> 1984 Feb; 43(2): 561-6.	
CM	Deierkauf F.A., et al.: "Phagocytosis by rabbit polymorphonuclear leukocytes: the effect of albumin and polyamino acids on latex uptake." <i>J Cell Physiol</i> 1977 Aug; 92(2): 169-75.	
CN	Di Nicola, M. et al.: "Large-scale feasibility of gene transduction into human CD34+ cell derived dendritic cells by adenoviral/polycation complex." <i>Br J Haematol</i> 2000 Oct; 111(1):344-50.	
CO	Buschle M. et al.: "Transloading of tumor antigen-derived peptides into antigen-presenting cells." <i>Proc Natl Acad Sci USA</i> 1997 Apr 1;94 (7): 3256-61.	
CP	Farmer, J.L. et al.: "Human immune response to cationized proteins. II. Characterization of interaction of cationized diphtheria toxin with human mononuclear cells." <i>Cell Immunol</i> 1993 Jan; 146(1): 198-209.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered	
--------------------	-----------------	--